Saint-Lary Laura, Diallo Alpha, de Monteynard Laure-Amélie, Paul Christelle, Marchand Lucie, Tubiana Roland, Warszawski Josiane, Mandelbrot Laurent, Rekacewicz Claire, Petrov-Sanchez Ventzislava, Faye Albert, Sibiude Jeanne, Dabis François, Sommet Agnès, Leroy Valériane
CERPOP, Inserm, Université de Toulouse, Université Paul Sabatier III, Toulouse, France.
Clinical Trial Safety and Public Health, ANRS, Paris, Île-de-France, France.
Br J Clin Pharmacol. 2022 Mar;88(3):942-964. doi: 10.1111/bcp.15075. Epub 2021 Oct 13.
In 2018, 1.07 million pregnant women received antiretroviral drugs, raising whether this affects pregnancy outcomes. We assessed the adverse pregnancy outcomes associated with prenatal antiretroviral drug exposure, notified to the French ANRS pharmacovigilance system.
An exhaustive case report series has been performed using the ANRS pharmacovigilance database. All ANRS-sponsored HIV clinical research studies using antiretroviral drugs either in pregnant women or women of childbearing age were eligible from 2004 to 2019. We analysed the following pregnancy outcomes: abortion, ectopic pregnancy, stillbirth, prematurity (<37 weeks of gestational age), low birth weight (<2500 g) and congenital abnormalities. A logistic regression was performed to assess the odds ratio (OR) for each outcome separately (if occurrence >50) compared to the outcome observed when exposed to non-nucleoside-reverse-transcriptase-inhibitor (NNRTI)-based regimen as the reference.
Among the 34 studies selected, 918 deliveries occurred, of whom 88% had pregnancy outcomes documented. Pregnant women were mainly exposed to PI (n = 387, 48.6%), NNRTI (n = 331, 41.5%) and INI-based combinations (n = 40, 5.0%, 18 on dolutegravir). Compared to NNRTI-based combinations, there was no significant association observed with exposure to other antiretroviral combination for spontaneous abortion, prematurity or low birth weight, except an increased risk of low birth weight in new-born exposed to exclusive nucleoside-reverse-transcriptase-inhibitor (NRTI) combinations (n = 4; OR 7.50 [1.49-37.83]).
Our study, mainly based on protease inhibitor (PI) and NNRTI-based regimens, is overall reassuring on the risk of adverse pregnancy outcomes, except for NRTI which should be interpreted cautiously (small number, indication bias). In this study, the number of integrase inhibitor (INI)-based combinations was too low to draw any conclusions.
2018年,107万孕妇接受了抗逆转录病毒药物治疗,这引发了其是否会影响妊娠结局的疑问。我们评估了法国ANRS药物警戒系统通报的与产前抗逆转录病毒药物暴露相关的不良妊娠结局。
使用ANRS药物警戒数据库进行了详尽的病例报告系列研究。2004年至2019年期间,所有由ANRS资助的、在孕妇或育龄妇女中使用抗逆转录病毒药物的HIV临床研究均符合条件。我们分析了以下妊娠结局:流产、宫外孕、死产、早产(孕周<37周)、低出生体重(<2500克)和先天性异常。进行了逻辑回归分析,以分别评估每种结局(如果发生率>50)与以非核苷类逆转录酶抑制剂(NNRTI)为基础的治疗方案作为对照时观察到的结局相比的比值比(OR)。
在所选的34项研究中,共发生了918例分娩,其中88%有记录的妊娠结局。孕妇主要暴露于蛋白酶抑制剂(PI)(n = 387,48.6%)、NNRTI(n = 331,41.5%)和基于整合酶抑制剂(INI)的联合用药(n = 40,5.0%,其中18例使用多替拉韦)。与基于NNRTI的联合用药相比,在自然流产、早产或低出生体重方面,未观察到与其他抗逆转录病毒联合用药暴露有显著关联,但暴露于单纯核苷类逆转录酶抑制剂(NRTI)联合用药的新生儿低出生体重风险增加(n = 4;OR 7.50 [1.49 - 37.83])。
我们的研究主要基于蛋白酶抑制剂(PI)和基于NNRTI的治疗方案,总体而言,除了NRTI应谨慎解读(数量少、存在指征偏倚)外,对不良妊娠结局风险令人放心。在本研究中,基于整合酶抑制剂(INI)的联合用药数量过少,无法得出任何结论。